MapLight Therapeutics, Inc.NASDAQ: MPLT

MapLight Therapeutics to Participate in Upcoming Investor Conference

· Issued by MapLight Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

MapLight Therapeutics, a clinical-stage drug developer focused on central nervous system disorders, said members of its management team will present and hold one-on-one investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY, on Monday, September 14.

Key details

  • Where available, live webcasts and archived recordings will be posted on the Events & Presentations page of the investor section of MapLight's website.

6ix AI wrote this summary from the release below and checked it against the release.

SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:

Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)
Date: Monday, September 14th
Format: Presenting and hosting 1x1 meetings

Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & Presentations" page on the Investor section of the company's website at https://ir.maplightrx.com/news-events/events-presentations.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company's discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.

For investor inquiries: [email protected]

For media inquiries: [email protected]

MapLight Therapeutics, Inc. on 6ix

Story so far

Earlier from MapLight Therapeutics

Later from MapLight Therapeutics

All MapLight Therapeutics news releases